The Norway Loophole
This article was originally published in Start Up
Executive Summary
Cambridge Antibody Technology has built a business based on an exclusive license to a key biotech patent on antibody expression libraries. But the patent holder, Medical Research Council, neglected to file for a patent in Norway. Enter Affitech, which has taken advantage of the loophole to obtain a patent on a more efficient way of creating and screening phage-derived antibody libraries and in the process creating new competition for CAT. Although Affitech can't sell the antibodies it screens outside of Norway, it claims it can legally sell optimized, already screened antibodies to anyone who wants them. And it believes it has an eager customer base.
You may also be interested in...
Leveraging Antibodies
Human antibodies are hot. Three leading companies with patented means for making them are battling for partners and strategic position, anxious to sign alliances before current competitors muscle in, or next-generation technologies come along. Abgenix and Medarex effectively share a duopoly on transgenic mice that make human antibodies. Both firms license their technologies on an antigen-by-antigen basis, but are moving to build more value by deploying the methods on their own behalf, and via 50/50 deals with companies willing to share targets and development costs. Cambridge Antibody Technology is the leading promoter of phage-display technology, a bacterially-based, relatively high throughput method of making human antibody fragments that can be used as reagents to validate targets, or built up into drugs. Owning products is the end-game for all three players. But their approaches to the goal differ, particularly in the way they're structuring deals and the number of products they intend to put into clinical development.
Engineering Protein Pharmaceuticals
Sophisticated protein engineering has largely been the domain of major biopharmaceutical companies. But genomics is flooding researchers with new proteins of unknown function and traditional techniques for turning them into drugs or for understanding their potential as drug targets are generally too slow. Start-ups around phage display, protein evolution, and synthetic protein chemistries are offering what look like faster, cheaper alternatives. But the size of the partnership opportunity for these new companies is uncertain, since drug companies still appear reluctant to embark on the development of protein drugs. In response, the start-ups are also trying to exploit the technologies for small-molecule drug discovery.
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.